Ortho Biotech
Executive Summary
Will operate as a separate company of Johnson & Johnson headed by Dennis Longstreet as president. The operation was previously a division of the J&J subsidiary, Ortho Pharmaceutical. Longstreet has been president of the division since early 1986. Ortho Biotech markets Orthoclone OKT-3 for reverse acute kidney transplantation rejection in the U.S. and sells Eprex (EPO) through J&J subsidiaries in 36 countries outside the U.S.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.